about
Vascular endothelial growth factor in systemic capillary leak syndrome.Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.Dendritic cell immunotherapy: mapping the way.Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results.Programmed death ligand 2 in cancer-induced immune suppression.Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.Transient Treg depletion enhances therapeutic anti-cancer vaccination.Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.Chemotherapy and immunotherapy: mapping the road ahead.Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines.Chemoimmunotherapy: still waiting for the magic to happen.Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma PatientsCombination immune checkpoint blockade as an effective therapy for mesotheliomaTargeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of CellsSkin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic MelanomaRoute of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma PatientsWild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide usedDendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma PatientsLimited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma PatientsIn situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patientsVaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin testsImmunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical OutcomeTumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptorsEBV-related lymphoproliferative disorders in immunocompetent patientsAcute generalised exanthematous pustulosis mimicking septic shockAcute arterial occlusion after chemotherapy for testicular cancerPD-L2 is predominantly expressed by Th2 cellsRecovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatmentComment on "drug discovery: turning the titanic"Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
P50
Q34017783-0E7EE0EE-4570-4068-8F57-45D727420852Q34145877-E476CEAD-16A0-448E-9F6E-590AD8AA1CF4Q35546673-9EA68CDC-FB0B-4C0F-B0E0-7FF6CE20E72FQ35762464-35B93421-BC0C-4148-B507-0DB9C561F16AQ35799065-641A3204-E457-40B0-89C6-1176D6606925Q35869292-E169C3CB-0FC5-49A2-A7D1-7739AF40E12CQ35914669-2424CA83-0CAC-4B08-AF8E-C9F36ABCFBF2Q35955151-5C27C4E4-181A-4D10-9ADF-2CA399AEA8C6Q36597517-158108BB-7986-4E3E-BD37-D4D0CBF716AFQ37660771-FFB58F01-C969-40ED-ABAA-092941BF30F0Q38216254-A848438C-6425-46BB-A55F-F796C478C533Q38685137-8FFBC2F5-9D7C-4455-9958-AA725FA9F9E5Q39069273-9DEB3D19-E0CC-4C0F-A256-C1BF2A18E66FQ41551997-A3B155F3-22AE-4C3D-A1C1-ECFB6E4FC2EBQ41575936-19E5BA73-495C-4341-BD35-21BC0D336047Q42690847-BD57CE5F-1FE2-4BA3-BC08-3A037F4A0BCBQ44137387-3EFDFE97-7EE0-4A33-82B6-B215C634C3A4Q45775114-84024815-6D07-4CE9-AEBF-32A98D009013Q48922480-52716DA1-E28D-4643-BB90-1BE5655390DBQ50804136-28533C9C-4CE1-462F-B7D8-5DD1D22F7D7CQ51101114-FC54E621-BD7F-4A57-A54C-A1ABD0751734Q56637518-D6E6F792-E2CC-4DBE-9AAE-4454BFF41858Q57138329-CB01269B-07C1-4334-A57D-3A96E163690DQ58619874-5D237A0D-049D-46D6-A10C-EB5B3A8B300BQ58619897-6C4B8172-47F7-4D5B-B619-AF2AEC38D461Q58619922-50E3FBDA-25DB-4686-83A4-4DAADE98CD0AQ58619928-DB4992DC-15EE-40EB-961F-2FF1F4DFDB0DQ58619940-EBC84D4C-AB51-46A5-80C8-3D961CD0FC50Q58619964-54FA2CB8-0EE1-44C5-9582-71996796731FQ58619995-18065D11-7443-4116-927E-3AFD5409C4FCQ58620029-54FC65A1-775B-4F3B-8B6D-205B6831DC55Q58620035-5BA3DFAC-362C-470E-B969-DC855AD1882DQ59791790-98750773-2A46-4B78-83E9-9085381427AAQ79108434-54495ADC-C02A-4215-B117-4DEB3EF5E954Q79869913-3C1DD74D-2C38-4D22-A255-1229641E29C0Q81418542-DE7969F2-3158-4961-9A09-8F658766BAEEQ82032236-9652EBD3-A8C9-4921-B8BD-63A04337DA71Q84968370-45877608-02AC-4221-95BC-9E8FB425D529Q87524136-950AF730-FE1E-4A6B-A05F-C4E010125DDEQ90836397-B615D77B-7B4D-48D8-ABB8-34B09D04E51D
P50
description
researcher ORCID ID = 0000-0002-2718-276X
@en
wetenschapper
@nl
name
Willem J Lesterhuis
@ast
Willem J Lesterhuis
@en
Willem J Lesterhuis
@es
Willem Lesterhuis
@nl
type
label
Willem J Lesterhuis
@ast
Willem J Lesterhuis
@en
Willem J Lesterhuis
@es
Willem Lesterhuis
@nl
altLabel
W. Lesterhuis
@nl
W.J. Lesterhuis
@nl
Willem J Lesterhuis
@nl
prefLabel
Willem J Lesterhuis
@ast
Willem J Lesterhuis
@en
Willem J Lesterhuis
@es
Willem Lesterhuis
@nl
P108
P106
P1153
6602103486
P31
P496
0000-0002-2718-276X